Home / Companies / GSK / Catalysts / Page 4 Catalysts · GSK · CIK 1131399 · page 4 of 4 GSK catalysts and FDA events, page 4. Updated November 16, 2026 Snapshot 20261116T222116Z Built 2026-11-16 22:21 UTC
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on GSK PDUFA dates and upcoming catalysts . This page continues the list.
Past catalysts and FDA decisions (continued) Date Drug Company Event Indication Status Source April 22, 2021 Jemperli (dostarlimab-gxly) GSK FDA approval — Approved openFDA Drugs@FDA March 1, 2021 Dovato (dolutegravir sodium; lamivudine) GSK Label expansion — Approved openFDA Drugs@FDA March 1, 2021 Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) GSK Label expansion — Approved openFDA Drugs@FDA January 21, 2021 Cabenuva Kit (cabotegravir; rilpivirine) GSK FDA approval — Approved openFDA Drugs@FDA January 21, 2021 Vocabria (cabotegravir sodium) GSK FDA approval — Approved openFDA Drugs@FDA December 16, 2020 Benlysta (belimumab) GSK Label expansion — Approved openFDA Drugs@FDA October 30, 2020 Selzentry (maraviroc) GSK Label expansion — Approved openFDA Drugs@FDA September 25, 2020 Nucala (mepolizumab) GSK Label expansion — Approved openFDA Drugs@FDA September 9, 2020 Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate) GSK Label expansion — Approved openFDA Drugs@FDA August 6, 2020 Dovato (dolutegravir sodium; lamivudine) GSK Label expansion — Approved openFDA Drugs@FDA July 14, 2020 Juluca (dolutegravir sodium; rilpivirine hydrochloride) GSK Label expansion — Approved openFDA Drugs@FDA July 2, 2020 Rukobia (fostemsavir tromethamine) GSK FDA approval — Approved openFDA Drugs@FDA June 12, 2020 Tivicay (dolutegravir sodium) GSK Label expansion — Approved openFDA Drugs@FDA June 12, 2020 Tivicay (dolutegravir sodium) GSK FDA approval — Approved openFDA Drugs@FDA April 29, 2020 ZEJULA (niraparib) GSK Label expansion — Approved openFDA Drugs@FDA December 19, 2019 Cabenuva Kit (cabotegravir; rilpivirine) GSK Complete Response Letter — CRL issued FDA Complete Response Letters December 19, 2019 Vocabria (cabotegravir sodium) GSK Complete Response Letter — CRL issued FDA Complete Response Letters June 6, 2019 Nucala (mepolizumab) GSK FDA approval — Approved openFDA Drugs@FDA April 8, 2019 Dovato (dolutegravir sodium; lamivudine) GSK FDA approval — Approved openFDA Drugs@FDA July 20, 2018 ARAKODA® (tafenoquine) GSK FDA approval — Approved openFDA Drugs@FDA November 21, 2017 Juluca (dolutegravir sodium; rilpivirine hydrochloride) GSK FDA approval — Approved openFDA Drugs@FDA September 18, 2017 Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate) GSK FDA approval — Approved openFDA Drugs@FDA July 20, 2017 Benlysta (belimumab) GSK FDA approval — Approved openFDA Drugs@FDA March 27, 2017 ZEJULA (niraparib) GSK FDA approval — Approved openFDA Drugs@FDA November 4, 2016 Selzentry (maraviroc) GSK FDA approval — Approved openFDA Drugs@FDA
FDA calendar PDUFA dates PDUFA calendar AdCom calendar FDA approvals today CRL tracker PDUFA outcomes dataset Indications Every catalyst is quoted from GSK’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.